-
In the first 11 months of 2022, the participation rate of basic medical insurance nationwide was stable at more than 95%.
Time of Update: 2023-02-02
The income of the basic medical insurance fund for urban and rural residents was 851.
The income of the basic medical insurance fund for urban and rural residents was 851.
The income of the basic medical insurance fund for urban and rural residents was 851.
-
NMPA solicits opinions on the Measures for the Administration of Drug Standards, and Chinese Pharmacopoeia and drug standards are national standards!
Time of Update: 2023-02-02
Chapter III: Planning and Project Establishment Article 16 (Work Plan for National Drug Standards) The drug regulatory department under the State Council shall organize the National Pharmacopoeia Commission to formulate the outline for the preparation of the Chinese Pharmacopoeia, which shall be implemented after deliberation and approval by the plenary meeting of the Pharmacopoeia Committee.
-
The National Medical Security Administration exposed typical cases in the first phase of 2023
Time of Update: 2023-02-02
93 yuan 。 According to the Regulations on the Supervision and Administration of the Use of Medical Security Funds and the Service Agreement of Designated Medical Institutions of Qinghai Province, the local medical insurance department handled the following results: 1.
-
The construction of the standard system of pharmaceutical packaging materials in the Chinese Pharmacopoeia has entered an intensive publicity period, and the National Pharmacopoeia Commission has issued 3 more announcements!
Time of Update: 2023-02-02
cn Mailing address: Office of the National Pharmacopoeia Commission, Building 11, Fahua Nanli, Dongcheng District, Beijing Zip code: 100061 National Pharmacopoeia Commission 2023-01-04 identification QR code viewing attachment On January 4, the National Pharmacopoeia Commission announced the draft of two general standards for prefilled syringes, nine draft standards for general detection methods for prefilled syringes, and draft standards for the determination of insoluble particles in pharmaceutical packaging materials.
-
Due to the failure to meet the expected data, some pharmaceutical companies announced the suspension of new drug research
Time of Update: 2023-02-02
js?cdnversion='+~(-new Date()/36e5)];Gene editing company Graphite Bio announced a voluntary moratorium on the phase 1/2 CEDAR study of nulabeglene autogedtemcel (nula-cell, GPH101) in sickle cell disease (SCD).
js?cdnversion='+~(-new Date()/36e5)];Gene editing company Graphite Bio announced a voluntary moratorium on the phase 1/2 CEDAR study of nulabeglene autogedtemcel (nula-cell, GPH101) in sickle cell disease (SCD).
-
CDE: Technical Guidelines for Immunogenicity Bridging Clinical Trials of Vaccines for Prevention (Draft for Comments) for comments
Time of Update: 2023-02-02
On December 21, the Center for Drug Evaluation of the State Food and Drug Administration publicly solicited comments on the "Technical Guidelines for Clinical Trials of Immunogenicity Bridging Clinical Trials of Preventive Vaccines (Draft for Comments)", and the time limit is one month from the date of issuance.
-
Global gene sequencing leader lowers 2023 performance guidance, the market is being "snapped up" by domestic enterprises
Time of Update: 2023-02-02
js?cdnversion='+~(-new Date()/36e5)];Recently, Illumina, the head manufacturer of global gene sequencing instruments, announced that it would lower its performance guidance for 2023 and was lower than market expectations.
-
Junshi PD-1 chases the deer in the Middle East! East China Pharmaceutical, Henlius, BeiGene...The "Belt and Road" market has become a blue ocean of innovative drugs in China?
Time of Update: 2023-02-02
On December 25, Junshi Biologics announced that it has reached a cooperation with Hikma MENA FZE (hereinafter referred to as "Hikma") for its PD-1 drug teripulimab. According to the announcement, Jun
-
Yang Sheng: Deepen the reform of drug review and approval and promote the high-quality development of the pharmaceutical industry
Time of Update: 2023-02-02
As China's drug regulatory reform has entered a new stage, in recent years, the State Drug Administration has issued a series of policies and regulations in deepening the reform of drug review and ap
-
Paxlovid health insurance negotiations were unsuccessful and the drugs were reimbursed
Time of Update: 2023-02-02
On the 8th, after several days of "soul haggling", the negotiation of the 2022 national medical insurance drug catalogue officially ended. According to news from the National Health Insurance Adminis
-
Pharmaceutical equipment enterprises and pharmaceutical companies continue to "marry" and jointly break the digital transformation and upgrading
Time of Update: 2023-02-02
Not long ago, Zhejiang Canaan Zhiyao officially signed a contract with Shenhua Pharmaceutical's oral liquid production line MES system project, and the two sides reached a strategic cooperation to jo
-
In 2022, the US FDA approved the inventory of innovative drugs: BMS, Roche, Legend Bio and other products were successfully launched
Time of Update: 2023-02-02
Hengrui Pharmaceutical has introduced the drug and submitted a new drug application in China in January this year BMS is another FIC drug On April 28, Bristol-Myers Squibb (BMS) mavacamten was approved by the FDA for the treatment of adult patients with obstructive hypertrophic cardiomyopathy (oHCM) rated class II-III according to the New York Heart Association's functional scale (NYHA) to improve exercise capacity and symptoms.
-
The sour jujube kernel market is running at a high level, and the health yuan needs to control the cost of raw materials!
Time of Update: 2023-02-02
According to the third quarterly report of 2022 released by Health Yuan Pharmaceutical Group Co. , Ltd. (Health Yuan, 600380), the operating income in the first three quarters of 2022 was 13. 012 bil
-
The traditional Chinese medicine tablet industry is accelerating the realization of the traceability system, and pharmaceutical equipment will be promising
Time of Update: 2023-02-02
Recently, the State Food and Drug Administration issued Several Measures on Further Strengthening the Scientific Supervision of Chinese Medicines and Promoting the Inheritance, Innovation and Develop
-
CDE is publicly soliciting comments on the Guidelines for Natural History Research of Diseases in Drug Development for Rare Diseases
Time of Update: 2023-02-02
Annex 2 "Guidelines for Natural History Research of Diseases in the Development of Rare Disease Drugs (Draft for Comments)" feedback form .
Annex 2 "Guidelines for Natural History Research of Diseases in the Development of Rare Disease Drugs (Draft for Comments)" feedback form .
-
$155 million, Pfizer joins hands with LianBio! Why is the RSV space attracting giants?
Time of Update: 2023-02-02
On December 19, Pfizer and LianBio announced that Pfizer will exercise its option to acquire the development and commercialization rights of respiratory syncytial virus (RSV) therapeutic candidate, s
-
Notice on the public solicitation of recommendations and Chinese version of ICH S1B(R1): Carcinogenicity Research
Time of Update: 2023-02-02
S1B (R1) English version Center for Drug Evaluation, State Medical Products Administration December 22, 2022In order to promote the smooth implementation of the newly revised ICH guidelines in China, our center has formulated the implementation recommendations of "S1B(R1): Carcinogenicity Research" and organized the translation of Chinese editions.
-
The global ophthalmic drug track competition has opened, and domestic pharmaceutical companies are increasing their layout
Time of Update: 2023-02-02
acquisition On January 9, Puri Eye announced that Dongguan Guangming Eye Hospital recently obtained the business license and "Registration Notice" issued by the Dongguan Market Supervision Administration, and the acquisition of 35% of the equity of Dongguan Guangming Eye Hospital by Chuangfa Enterprise has completed the registration procedures for industrial and commercial changes.
-
Recently, there has been good news that generic drugs of pharmaceutical companies have been evaluated and approved for the first generics
Time of Update: 2023-02-02
Recently, Hanyu Pharmaceutical issued an announcement that the company received the "Drug Registration Certificate" issued by the State Medical Products Administration, and the company's hypoglycemic drug "vildagliptin tablets" was approved for marketing and deemed to have passed the consistency evaluation.
-
At the beginning of the new year, the pharmaceutical industry has begun to set off a wave of repurchases!
Time of Update: 2023-02-02
On January 9, Guizhou Bailing announced that it intends to repurchase the company's shares for 100 million to 200 million yuan for the later implementation of equity incentives or employee stock ownership plans.
